Global Therapeutic Peptide APIs Market Outlook, In‑Depth Analysis & Forecast to 2031

1 Study Coverage
1.1 Introduction to Therapeutic Peptide APIs: Definition, Properties, and Key Attributes
1.2 Market Segmentation by Type
1.2.1 Global Therapeutic Peptide APIs Market Size by Type, 2020 VS 2024 VS 2031
1.2.2 Bioactive Peptides
1.2.3 Synthetic Peptides
1.3 Market Segmentation by Application
1.3.1 Global Therapeutic Peptide APIs Market Size by Application, 2020 VS 2024 VS 2031
1.3.2 Pharmaceuticals
1.3.3 Scientific Research
1.3.4 Other
1.4 Assumptions and Limitations
1.5 Study Objectives
1.6 Years Considered
2 Executive Summary
2.1 Global Therapeutic Peptide APIs Revenue Estimates and Forecasts 2020-2031
2.2 Global Therapeutic Peptide APIs Revenue by Region
2.2.1 Revenue Comparison: 2020 VS 2024 VS 2031
2.2.2 Historical and Forecasted Revenue by Region (2020--2031)
2.2.3 Global Revenue Market Share by Region (2020-2031)
2.3 Global Therapeutic Peptide APIs Sales Estimates and Forecasts 2020-2031
2.4 Global Therapeutic Peptide APIs Sales by Region
2.4.1 Sales Comparison: 2020 VS 2024 VS 2031
2.4.2 Historical and Forecasted Sales by Region (2020-2031)
2.4.3 Emerging Market Focus: Growth Drivers & Investment Trends
2.4.4 Global Sales Market Share by Region (2020-2031)
3 Competition by Manufacturers
3.1 Global Therapeutic Peptide APIs Sales by Manufacturers
3.1.1 Global Sales Volume by Manufacturers (2020-2025)
3.1.2 Global Top 5 and Top 10 Manufacturers’Market Share by Sales Volume (2024)
3.2 Global Therapeutic Peptide APIs Manufacturer Revenue Rankings and Tiers
3.2.1 Global Revenue (Value) by Manufacturers (2020-2025)
3.2.2 Global Key Manufacturer Revenue Ranking (2023 vs. 2024)
3.2.3 Revenue-Based Tier Segmentation (Tier 1, Tier 2, and Tier 3)
3.3 Manufacturer Profitability Profiles and Pricing Strategies
3.3.1 Gross Margin by Top Manufacturer (2020 VS 2024)
3.3.2 Manufacturer-Level Price Trends (2020-2025)
3.4 Key Manufacturers Manufacturing Base and Headquarters
3.5 Main Product Type Market Size by Manufacturers
3.5.1 Bioactive Peptides Market Size by Manufacturers
3.5.2 Synthetic Peptides Market Size by Manufacturers
3.6 Global Therapeutic Peptide APIs Market Concentration and Dynamics
3.6.1 Global Market Concentration (CR5 and HHI)
3.6.2 Entrant/Exit Impact Analysis
3.6.3 Strategic Moves: M&A, Capacity Expansion, R&D Investment
4 Global Product Segmentation Analysis
4.1 Global Therapeutic Peptide APIs Sales Performance by Type
4.1.1 Global Historical and Forecasted Sales by Type (2020-2031)
4.1.2 Global Sales Market Share by Type (2020-2031)
4.2 Global Therapeutic Peptide APIs Revenue Trends by Type
4.2.1 Global Historical and Forecasted Revenue by Type (2020-2031)
4.2.2 Global Revenue Market Share by Type (2020-2031)
4.3 Global Average Selling Price (ASP) Trends by Type (2020-2031)
4.4 Product Technology Differentiation
4.5 Subtype Dynamics: Growth Leaders, Profitability and Risk
4.5.1 High-Growth Niches and Adoption Drivers
4.5.2 Profitability Hotspots and Cost Drivers
4.5.3 Substitution Threats
5 Global Downstream Application Analysis
5.1 Global Therapeutic Peptide APIs Sales by Application
5.1.1 Global Historical and Forecasted Sales by Application (2020-2031)
5.1.2 Global Sales Market Share by Application (2020-2031)
5.1.3 High-Growth Application Identification
5.1.4 Emerging Application Case Studies
5.2 Global Therapeutic Peptide APIs Revenue by Application
5.2.1 Global Historical and Forecasted Revenue by Application (2020-2031)
5.2.2 Revenue Market Share by Application (2020-2031)
5.3 Global Pricing Dynamics by Application (2020-2031)
5.4 Downstream Customer Analysis
5.4.1 Top Customers by Region
5.4.2 Top Customers by Application
6 North America
6.1 North America Sales Volume and Revenue (2020-2031)
6.2 North America Key Manufacturers Sales Revenue in 2024
6.3 North America Therapeutic Peptide APIs Sales and Revenue by Type (2020-2031)
6.4 North America Therapeutic Peptide APIs Sales and Revenue by Application (2020-2031)
6.5 North America Growth Accelerators and Market Barriers
6.6 North America Therapeutic Peptide APIs Market Size by Country
6.6.1 North America Revenue by Country
6.6.2 North America Sales Trends by Country
6.6.3 US
6.6.4 Canada
6.6.5 Mexico
7 Europe
7.1 Europe Sales Volume and Revenue (2020-2031)
7.2 Europe Key Manufacturers Sales Revenue in 2024
7.3 Europe Therapeutic Peptide APIs Sales and Revenue by Type (2020-2031)
7.4 Europe Therapeutic Peptide APIs Sales and Revenue by Application (2020-2031)
7.5 Europe Growth Accelerators and Market Barriers
7.6 Europe Therapeutic Peptide APIs Market Size by Country
7.6.1 Europe Revenue by Country
7.6.2 Europe Sales Trends by Country
7.6.3 Germany
7.6.4 France
7.6.5 U.K.
7.6.6 Italy
7.6.7 Russia
8 Asia-Pacific
8.1 Asia-Pacific Sales Volume and Revenue (2020-2031)
8.2 Asia-Pacific Key Manufacturers Sales Revenue in 2024
8.3 Asia-Pacific Therapeutic Peptide APIs Sales and Revenue by Type (2020-2031)
8.4 Asia-Pacific Therapeutic Peptide APIs Sales and Revenue by Application (2020-2031)
8.5 Asia-Pacific Therapeutic Peptide APIs Market Size by Region
8.5.1 Asia-Pacific Revenue by Region
8.5.2 Asia-Pacific Sales Trends by Region
8.6 Asia-Pacific Growth Accelerators and Market Barriers
8.7 Southeast Asia
8.7.1 Southeast Asia Revenue by Country (2020 VS 2024 VS 2031)
8.7.2 Key Country Analysis: Indonesia, Vietnam, Thailand, Malaysia, Philippines
8.8 China
8.9 Japan
8.10 South Korea
8.11 China Taiwan
8.12 India
9 Central and South America
9.1 Central and South America Sales Volume and Revenue (2020-2031)
9.2 Central and South America Key Manufacturers Sales Revenue in 2024
9.3 Central and South America Therapeutic Peptide APIs Sales and Revenue by Type (2020-2031)
9.4 Central and South America Therapeutic Peptide APIs Sales and Revenue by Application (2020-2031)
9.5 Central and South America Investment Opportunities and Key Challenges
9.6 Central and South America Therapeutic Peptide APIs Market Size by Country
9.6.1 Central and South America Revenue Trends by Country (2020 VS 2024 VS 2031)
9.6.2 Brazil
9.6.3 Argentina
10 Middle East and Africa
10.1 Middle East and Africa Sales Volume and Revenue (2020-2031)
10.2 Middle East and Africa Key Manufacturers Sales Revenue in 2024
10.3 Middle East and Africa Therapeutic Peptide APIs Sales and Revenue by Type (2020-2031)
10.4 Middle East and Africa Therapeutic Peptide APIs Sales and Revenue by Application (2020-2031)
10.5 Middle East and Africa Investment Opportunities and Key Challenges
10.6 Middle East and Africa Therapeutic Peptide APIs Market Size by Country
10.6.1 Middle East and Africa Revenue Trends by Country (2020 VS 2024 VS 2031)
10.6.2 GCC Countries
10.6.3 Turkey
10.6.4 Egypt
10.6.5 South Africa
11 Corporate Profile
11.1 Bachem
11.1.1 Bachem Corporation Information
11.1.2 Bachem Business Overview
11.1.3 Bachem Therapeutic Peptide APIs Product Models, Descriptions and Specifications
11.1.4 Bachem Therapeutic Peptide APIs Sales, Price, Revenue and Gross Margin (2020-2025)
11.1.5 Bachem Therapeutic Peptide APIs Sales by Product in 2024
11.1.6 Bachem Therapeutic Peptide APIs Sales by Application in 2024
11.1.7 Bachem Therapeutic Peptide APIs Sales by Geographic Area in 2024
11.1.8 Bachem Therapeutic Peptide APIs SWOT Analysis
11.1.9 Bachem Recent Developments
11.2 GenScript
11.2.1 GenScript Corporation Information
11.2.2 GenScript Business Overview
11.2.3 GenScript Therapeutic Peptide APIs Product Models, Descriptions and Specifications
11.2.4 GenScript Therapeutic Peptide APIs Sales, Price, Revenue and Gross Margin (2020-2025)
11.2.5 GenScript Therapeutic Peptide APIs Sales by Product in 2024
11.2.6 GenScript Therapeutic Peptide APIs Sales by Application in 2024
11.2.7 GenScript Therapeutic Peptide APIs Sales by Geographic Area in 2024
11.2.8 GenScript Therapeutic Peptide APIs SWOT Analysis
11.2.9 GenScript Recent Developments
11.3 AmbioPharm
11.3.1 AmbioPharm Corporation Information
11.3.2 AmbioPharm Business Overview
11.3.3 AmbioPharm Therapeutic Peptide APIs Product Models, Descriptions and Specifications
11.3.4 AmbioPharm Therapeutic Peptide APIs Sales, Price, Revenue and Gross Margin (2020-2025)
11.3.5 AmbioPharm Therapeutic Peptide APIs Sales by Product in 2024
11.3.6 AmbioPharm Therapeutic Peptide APIs Sales by Application in 2024
11.3.7 AmbioPharm Therapeutic Peptide APIs Sales by Geographic Area in 2024
11.3.8 AmbioPharm Therapeutic Peptide APIs SWOT Analysis
11.3.9 AmbioPharm Recent Developments
11.4 Limitless Biotech
11.4.1 Limitless Biotech Corporation Information
11.4.2 Limitless Biotech Business Overview
11.4.3 Limitless Biotech Therapeutic Peptide APIs Product Models, Descriptions and Specifications
11.4.4 Limitless Biotech Therapeutic Peptide APIs Sales, Price, Revenue and Gross Margin (2020-2025)
11.4.5 Limitless Biotech Therapeutic Peptide APIs Sales by Product in 2024
11.4.6 Limitless Biotech Therapeutic Peptide APIs Sales by Application in 2024
11.4.7 Limitless Biotech Therapeutic Peptide APIs Sales by Geographic Area in 2024
11.4.8 Limitless Biotech Therapeutic Peptide APIs SWOT Analysis
11.4.9 Limitless Biotech Recent Developments
11.5 CPC Scientific
11.5.1 CPC Scientific Corporation Information
11.5.2 CPC Scientific Business Overview
11.5.3 CPC Scientific Therapeutic Peptide APIs Product Models, Descriptions and Specifications
11.5.4 CPC Scientific Therapeutic Peptide APIs Sales, Price, Revenue and Gross Margin (2020-2025)
11.5.5 CPC Scientific Therapeutic Peptide APIs Sales by Product in 2024
11.5.6 CPC Scientific Therapeutic Peptide APIs Sales by Application in 2024
11.5.7 CPC Scientific Therapeutic Peptide APIs Sales by Geographic Area in 2024
11.5.8 CPC Scientific Therapeutic Peptide APIs SWOT Analysis
11.5.9 CPC Scientific Recent Developments
11.6 PolyPeptide
11.6.1 PolyPeptide Corporation Information
11.6.2 PolyPeptide Business Overview
11.6.3 PolyPeptide Therapeutic Peptide APIs Product Models, Descriptions and Specifications
11.6.4 PolyPeptide Therapeutic Peptide APIs Sales, Price, Revenue and Gross Margin (2020-2025)
11.6.5 PolyPeptide Recent Developments
11.7 CordenPharma
11.7.1 CordenPharma Corporation Information
11.7.2 CordenPharma Business Overview
11.7.3 CordenPharma Therapeutic Peptide APIs Product Models, Descriptions and Specifications
11.7.4 CordenPharma Therapeutic Peptide APIs Sales, Price, Revenue and Gross Margin (2020-2025)
11.7.5 CordenPharma Recent Developments
11.8 Lonza
11.8.1 Lonza Corporation Information
11.8.2 Lonza Business Overview
11.8.3 Lonza Therapeutic Peptide APIs Product Models, Descriptions and Specifications
11.8.4 Lonza Therapeutic Peptide APIs Sales, Price, Revenue and Gross Margin (2020-2025)
11.8.5 Lonza Recent Developments
11.9 Aspen API
11.9.1 Aspen API Corporation Information
11.9.2 Aspen API Business Overview
11.9.3 Aspen API Therapeutic Peptide APIs Product Models, Descriptions and Specifications
11.9.4 Aspen API Therapeutic Peptide APIs Sales, Price, Revenue and Gross Margin (2020-2025)
11.9.5 Aspen API Recent Developments
11.10 Syngene
11.10.1 Syngene Corporation Information
11.10.2 Syngene Business Overview
11.10.3 Syngene Therapeutic Peptide APIs Product Models, Descriptions and Specifications
11.10.4 Syngene Therapeutic Peptide APIs Sales, Price, Revenue and Gross Margin (2020-2025)
11.10.5 Syngene Recent Developments
11.11 USV Peptides
11.11.1 USV Peptides Corporation Information
11.11.2 USV Peptides Business Overview
11.11.3 USV Peptides Therapeutic Peptide APIs Product Models, Descriptions and Specifications
11.11.4 USV Peptides Therapeutic Peptide APIs Sales, Price, Revenue and Gross Margin (2020-2025)
11.11.5 USV Peptides Recent Developments
11.12 Bio Basic
11.12.1 Bio Basic Corporation Information
11.12.2 Bio Basic Business Overview
11.12.3 Bio Basic Therapeutic Peptide APIs Product Models, Descriptions and Specifications
11.12.4 Bio Basic Therapeutic Peptide APIs Sales, Price, Revenue and Gross Margin (2020-2025)
11.12.5 Bio Basic Recent Developments
11.13 JPT Peptide Technologies
11.13.1 JPT Peptide Technologies Corporation Information
11.13.2 JPT Peptide Technologies Business Overview
11.13.3 JPT Peptide Technologies Therapeutic Peptide APIs Product Models, Descriptions and Specifications
11.13.4 JPT Peptide Technologies Therapeutic Peptide APIs Sales, Price, Revenue and Gross Margin (2020-2025)
11.13.5 JPT Peptide Technologies Recent Developments
11.14 ScinoPharm
11.14.1 ScinoPharm Corporation Information
11.14.2 ScinoPharm Business Overview
11.14.3 ScinoPharm Therapeutic Peptide APIs Product Models, Descriptions and Specifications
11.14.4 ScinoPharm Therapeutic Peptide APIs Sales, Price, Revenue and Gross Margin (2020-2025)
11.14.5 ScinoPharm Recent Developments
11.15 Piramal Pharma
11.15.1 Piramal Pharma Corporation Information
11.15.2 Piramal Pharma Business Overview
11.15.3 Piramal Pharma Therapeutic Peptide APIs Product Models, Descriptions and Specifications
11.15.4 Piramal Pharma Therapeutic Peptide APIs Sales, Price, Revenue and Gross Margin (2020-2025)
11.15.5 Piramal Pharma Recent Developments
11.16 Jiangsu Sinopep-Allsino Biopharmaceutical
11.16.1 Jiangsu Sinopep-Allsino Biopharmaceutical Corporation Information
11.16.2 Jiangsu Sinopep-Allsino Biopharmaceutical Business Overview
11.16.3 Jiangsu Sinopep-Allsino Biopharmaceutical Therapeutic Peptide APIs Product Models, Descriptions and Specifications
11.16.4 Jiangsu Sinopep-Allsino Biopharmaceutical Therapeutic Peptide APIs Sales, Price, Revenue and Gross Margin (2020-2025)
11.16.5 Jiangsu Sinopep-Allsino Biopharmaceutical Recent Developments
11.17 Cheng Du Sheng Nuo Biotec
11.17.1 Cheng Du Sheng Nuo Biotec Corporation Information
11.17.2 Cheng Du Sheng Nuo Biotec Business Overview
11.17.3 Cheng Du Sheng Nuo Biotec Therapeutic Peptide APIs Product Models, Descriptions and Specifications
11.17.4 Cheng Du Sheng Nuo Biotec Therapeutic Peptide APIs Sales, Price, Revenue and Gross Margin (2020-2025)
11.17.5 Cheng Du Sheng Nuo Biotec Recent Developments
11.18 Hybio Pharmaceutical
11.18.1 Hybio Pharmaceutical Corporation Information
11.18.2 Hybio Pharmaceutical Business Overview
11.18.3 Hybio Pharmaceutical Therapeutic Peptide APIs Product Models, Descriptions and Specifications
11.18.4 Hybio Pharmaceutical Therapeutic Peptide APIs Sales, Price, Revenue and Gross Margin (2020-2025)
11.18.5 Hybio Pharmaceutical Recent Developments
11.19 Hainan Shuangcheng Pharmaceuticals
11.19.1 Hainan Shuangcheng Pharmaceuticals Corporation Information
11.19.2 Hainan Shuangcheng Pharmaceuticals Business Overview
11.19.3 Hainan Shuangcheng Pharmaceuticals Therapeutic Peptide APIs Product Models, Descriptions and Specifications
11.19.4 Hainan Shuangcheng Pharmaceuticals Therapeutic Peptide APIs Sales, Price, Revenue and Gross Margin (2020-2025)
11.19.5 Hainan Shuangcheng Pharmaceuticals Recent Developments
11.20 Guangdong Jianyuan Pharmaceutical
11.20.1 Guangdong Jianyuan Pharmaceutical Corporation Information
11.20.2 Guangdong Jianyuan Pharmaceutical Business Overview
11.20.3 Guangdong Jianyuan Pharmaceutical Therapeutic Peptide APIs Product Models, Descriptions and Specifications
11.20.4 Guangdong Jianyuan Pharmaceutical Therapeutic Peptide APIs Sales, Price, Revenue and Gross Margin (2020-2025)
11.20.5 Guangdong Jianyuan Pharmaceutical Recent Developments
11.21 Zhejiang Peptites Biotech
11.21.1 Zhejiang Peptites Biotech Corporation Information
11.21.2 Zhejiang Peptites Biotech Business Overview
11.21.3 Zhejiang Peptites Biotech Therapeutic Peptide APIs Product Models, Descriptions and Specifications
11.21.4 Zhejiang Peptites Biotech Therapeutic Peptide APIs Sales, Price, Revenue and Gross Margin (2020-2025)
11.21.5 Zhejiang Peptites Biotech Recent Developments
12 Value Chain and Supply-Chain Analysis
12.1 Therapeutic Peptide APIs Industry Chain
12.2 Therapeutic Peptide APIs Upstream Materials Analysis
12.2.1 Raw Materials
12.2.2 Key Suppliers Market Share & Risk Assessment
12.3 Therapeutic Peptide APIs Integrated Production Analysis
12.3.1 Manufacturing Footprint Analysis
12.3.2 Regional Production Market Share (2020-2031)
12.3.3 Regulatory and Trade Policy Impact on Production
12.3.4 Production Technology Overview
12.3.5 Regional Cost Drivers
12.4 Therapeutic Peptide APIs Sales Channels and Distribution Networks
12.4.1 Sales Channels
12.4.2 Distributors
13 Therapeutic Peptide APIs Market Dynamics
13.1 Industry Trends and Evolution
13.2 Market Growth Drivers and Emerging Opportunities
13.3 Market Challenges, Risks, and Restraints
14 Key Findings in the Global Therapeutic Peptide APIs Study
15 Appendix
15.1 Research Methodology
15.1.1 Methodology/Research Approach
15.1.1.1 Research Programs/Design
15.1.1.2 Market Size Estimation
15.1.1.3 Market Breakdown and Data Triangulation
15.1.2 Data Source
15.1.2.1 Secondary Sources
15.1.2.2 Primary Sources
15.2 Author Details

List of Tables
Table 1. Global Therapeutic Peptide APIs Market Size Growth Rate by Type, 2020 VS 2024 VS 2031 (US$ Million)
Table 2. Global Therapeutic Peptide APIs Market Size Growth Rate by Application, 2020 VS 2024 VS 2031 (US$ Million)
Table 3. Global Therapeutic Peptide APIs Revenue Grow Rate (CAGR) by Region: 2020 VS 2024 VS 2031 (US$ Million)
Table 4. Global Therapeutic Peptide APIs Revenue by Region (2020-2025) & (US$ Million)
Table 5. Global Therapeutic Peptide APIs Revenue by Region (2026-2031) & (US$ Million)
Table 6. Global Therapeutic Peptide APIs Sales Grow Rate (CAGR) by Region: 2020 VS 2024 VS 2031 (Tons)
Table 7. Global Therapeutic Peptide APIs Sales by Region (2020-2025) & (Tons)
Table 8. Global Therapeutic Peptide APIs Sales by Region (2026-2031) & (Tons)
Table 9. Emerging Market Revenue Grow Rate (CAGR) by Country (2020 VS 2024 VS 2031) (US$ Million)
Table 10. Global Therapeutic Peptide APIs Sales by Manufacturers (2020-2025) & (Tons)
Table 11. Global Therapeutic Peptide APIs Sales Share by Manufacturers (2020-2025)
Table 12. Global Therapeutic Peptide APIs Revenue by Manufacturers (2020-2025) & (US$ Million)
Table 13. Global Therapeutic Peptide APIs Revenue Market Share by Manufacturers (2020-2025)
Table 14. Global Key Manufacturers’Ranking Shift (2023 vs. 2024) (Based on Revenue)
Table 15. Global Therapeutic Peptide APIs by Manufacturer Tier (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Therapeutic Peptide APIs as of 2024)
Table 16. Global Therapeutic Peptide APIs Average Gross Margin (%) by Manufacturer (2020 VS 2024)
Table 17. Global Therapeutic Peptide APIs Average Selling Price (ASP) by Manufacturers (2020-2025) & (US$/kg)
Table 18. Key Manufacturers Therapeutic Peptide APIs Manufacturing Base and Headquarters
Table 19. Global Therapeutic Peptide APIs Market Concentration Ratio (CR5 and HHI)
Table 20. Key Market Entrant/Exit (2020-2024) – Drivers & Impact Analysis
Table 21. Key Mergers & Acquisitions, Expansion Plans, R&D Investment
Table 22. Global Therapeutic Peptide APIs Sales by Type (2020-2025) & (Tons)
Table 23. Global Therapeutic Peptide APIs Sales by Type (2026-2031) & (Tons)
Table 24. Global Therapeutic Peptide APIs Revenue by Type (2020-2025) & (US$ Million)
Table 25. Global Therapeutic Peptide APIs Revenue by Type (2026-2031) & (US$ Million)
Table 26. Global Therapeutic Peptide APIs ASP by Type (2020-2031) & (US$/kg)
Table 27. Technical Specifications by Key Product Type
Table 28. Global Therapeutic Peptide APIs Sales by Application (2020-2025) & (Tons)
Table 29. Global Therapeutic Peptide APIs Sales by Application (2026-2031) & (Tons)
Table 30. Therapeutic Peptide APIs High-Growth Sectors Demand CAGR (2024-2031)
Table 31. Global Therapeutic Peptide APIs Revenue by Application (2020-2025) & (US$ Million)
Table 32. Global Therapeutic Peptide APIs Revenue by Application (2026-2031) & (US$ Million)
Table 33. Global Therapeutic Peptide APIs ASP by Application (2020-2031) & (US$/kg)
Table 34. Top Customers by Region
Table 35. Top Customers by Application
Table 36. North America Therapeutic Peptide APIs Growth Accelerators and Market Barriers
Table 37. North America Therapeutic Peptide APIs Revenue Grow Rate (CAGR) by Country (2020 VS 2024 VS 2031) (US$ Million)
Table 38. North America Therapeutic Peptide APIs Sales (Tons) by Country (2020 VS 2024 VS 2031)
Table 39. Europe Therapeutic Peptide APIs Growth Accelerators and Market Barriers
Table 40. Europe Therapeutic Peptide APIs Revenue Grow Rate (CAGR) by Country: 2020 VS 2024 VS 2031 (US$ Million)
Table 41. Europe Therapeutic Peptide APIs Sales (Tons) by Country (2020 VS 2024 VS 2031)
Table 42. Asia-Pacific Therapeutic Peptide APIs Revenue Grow Rate (CAGR) by Region: 2020 VS 2024 VS 2031 (US$ Million)
Table 43. Asia-Pacific Therapeutic Peptide APIs Sales (Tons) by Country (2020 VS 2024 VS 2031)
Table 44. Asia-Pacific Therapeutic Peptide APIs Growth Accelerators and Market Barriers
Table 45. Southeast Asia Therapeutic Peptide APIs Revenue Grow Rate (CAGR) by Region: 2020 VS 2024 VS 2031 (US$ Million)
Table 46. Central and South America Therapeutic Peptide APIs Investment Opportunities and Key Challenges
Table 47. Central and South America Therapeutic Peptide APIs Revenue Grow Rate (CAGR) by Country (2020 VS 2024 VS 2031) (US$ Million)
Table 48. Middle East and Africa Therapeutic Peptide APIs Investment Opportunities and Key Challenges
Table 49. Middle East and Africa Therapeutic Peptide APIs Revenue Grow Rate (CAGR) by Country (2020 VS 2024 VS 2031) (US$ Million)
Table 50. Bachem Corporation Information
Table 51. Bachem Description and Major Businesses
Table 52. Bachem Product Models, Descriptions and Specifications
Table 53. Bachem Sales (Tons), Revenue (US$ Million), Price (US$/kg) and Gross Margin (2020-2025)
Table 54. Bachem Sales Value Proportion by Product in 2024
Table 55. Bachem Sales Value Proportion by Application in 2024
Table 56. Bachem Sales Value Proportion by Geographic Area in 2024
Table 57. Bachem Therapeutic Peptide APIs SWOT Analysis
Table 58. Bachem Recent Developments
Table 59. GenScript Corporation Information
Table 60. GenScript Description and Major Businesses
Table 61. GenScript Product Models, Descriptions and Specifications
Table 62. GenScript Sales (Tons), Revenue (US$ Million), Price (US$/kg) and Gross Margin (2020-2025)
Table 63. GenScript Sales Value Proportion by Product in 2024
Table 64. GenScript Sales Value Proportion by Application in 2024
Table 65. GenScript Sales Value Proportion by Geographic Area in 2024
Table 66. GenScript Therapeutic Peptide APIs SWOT Analysis
Table 67. GenScript Recent Developments
Table 68. AmbioPharm Corporation Information
Table 69. AmbioPharm Description and Major Businesses
Table 70. AmbioPharm Product Models, Descriptions and Specifications
Table 71. AmbioPharm Sales (Tons), Revenue (US$ Million), Price (US$/kg) and Gross Margin (2020-2025)
Table 72. AmbioPharm Sales Value Proportion by Product in 2024
Table 73. AmbioPharm Sales Value Proportion by Application in 2024
Table 74. AmbioPharm Sales Value Proportion by Geographic Area in 2024
Table 75. AmbioPharm Therapeutic Peptide APIs SWOT Analysis
Table 76. AmbioPharm Recent Developments
Table 77. Limitless Biotech Corporation Information
Table 78. Limitless Biotech Description and Major Businesses
Table 79. Limitless Biotech Product Models, Descriptions and Specifications
Table 80. Limitless Biotech Sales (Tons), Revenue (US$ Million), Price (US$/kg) and Gross Margin (2020-2025)
Table 81. Limitless Biotech Sales Value Proportion by Product in 2024
Table 82. Limitless Biotech Sales Value Proportion by Application in 2024
Table 83. Limitless Biotech Sales Value Proportion by Geographic Area in 2024
Table 84. Limitless Biotech Therapeutic Peptide APIs SWOT Analysis
Table 85. Limitless Biotech Recent Developments
Table 86. CPC Scientific Corporation Information
Table 87. CPC Scientific Description and Major Businesses
Table 88. CPC Scientific Product Models, Descriptions and Specifications
Table 89. CPC Scientific Sales (Tons), Revenue (US$ Million), Price (US$/kg) and Gross Margin (2020-2025)
Table 90. CPC Scientific Sales Value Proportion by Product in 2024
Table 91. CPC Scientific Sales Value Proportion by Application in 2024
Table 92. CPC Scientific Sales Value Proportion by Geographic Area in 2024
Table 93. CPC Scientific Therapeutic Peptide APIs SWOT Analysis
Table 94. CPC Scientific Recent Developments
Table 95. PolyPeptide Corporation Information
Table 96. PolyPeptide Description and Major Businesses
Table 97. PolyPeptide Product Models, Descriptions and Specifications
Table 98. PolyPeptide Sales (Tons), Revenue (US$ Million), Price (US$/kg) and Gross Margin (2020-2025)
Table 99. PolyPeptide Recent Developments
Table 100. CordenPharma Corporation Information
Table 101. CordenPharma Description and Major Businesses
Table 102. CordenPharma Product Models, Descriptions and Specifications
Table 103. CordenPharma Sales (Tons), Revenue (US$ Million), Price (US$/kg) and Gross Margin (2020-2025)
Table 104. CordenPharma Recent Developments
Table 105. Lonza Corporation Information
Table 106. Lonza Description and Major Businesses
Table 107. Lonza Product Models, Descriptions and Specifications
Table 108. Lonza Sales (Tons), Revenue (US$ Million), Price (US$/kg) and Gross Margin (2020-2025)
Table 109. Lonza Recent Developments
Table 110. Aspen API Corporation Information
Table 111. Aspen API Description and Major Businesses
Table 112. Aspen API Product Models, Descriptions and Specifications
Table 113. Aspen API Sales (Tons), Revenue (US$ Million), Price (US$/kg) and Gross Margin (2020-2025)
Table 114. Aspen API Recent Developments
Table 115. Syngene Corporation Information
Table 116. Syngene Description and Major Businesses
Table 117. Syngene Product Models, Descriptions and Specifications
Table 118. Syngene Sales (Tons), Revenue (US$ Million), Price (US$/kg) and Gross Margin (2020-2025)
Table 119. Syngene Recent Developments
Table 120. USV Peptides Corporation Information
Table 121. USV Peptides Description and Major Businesses
Table 122. USV Peptides Product Models, Descriptions and Specifications
Table 123. USV Peptides Sales (Tons), Revenue (US$ Million), Price (US$/kg) and Gross Margin (2020-2025)
Table 124. USV Peptides Recent Developments
Table 125. Bio Basic Corporation Information
Table 126. Bio Basic Description and Major Businesses
Table 127. Bio Basic Product Models, Descriptions and Specifications
Table 128. Bio Basic Sales (Tons), Revenue (US$ Million), Price (US$/kg) and Gross Margin (2020-2025)
Table 129. Bio Basic Recent Developments
Table 130. JPT Peptide Technologies Corporation Information
Table 131. JPT Peptide Technologies Description and Major Businesses
Table 132. JPT Peptide Technologies Product Models, Descriptions and Specifications
Table 133. JPT Peptide Technologies Sales (Tons), Revenue (US$ Million), Price (US$/kg) and Gross Margin (2020-2025)
Table 134. JPT Peptide Technologies Recent Developments
Table 135. ScinoPharm Corporation Information
Table 136. ScinoPharm Description and Major Businesses
Table 137. ScinoPharm Product Models, Descriptions and Specifications
Table 138. ScinoPharm Sales (Tons), Revenue (US$ Million), Price (US$/kg) and Gross Margin (2020-2025)
Table 139. ScinoPharm Recent Developments
Table 140. Piramal Pharma Corporation Information
Table 141. Piramal Pharma Description and Major Businesses
Table 142. Piramal Pharma Product Models, Descriptions and Specifications
Table 143. Piramal Pharma Sales (Tons), Revenue (US$ Million), Price (US$/kg) and Gross Margin (2020-2025)
Table 144. Piramal Pharma Recent Developments
Table 145. Jiangsu Sinopep-Allsino Biopharmaceutical Corporation Information
Table 146. Jiangsu Sinopep-Allsino Biopharmaceutical Description and Major Businesses
Table 147. Jiangsu Sinopep-Allsino Biopharmaceutical Product Models, Descriptions and Specifications
Table 148. Jiangsu Sinopep-Allsino Biopharmaceutical Sales (Tons), Revenue (US$ Million), Price (US$/kg) and Gross Margin (2020-2025)
Table 149. Jiangsu Sinopep-Allsino Biopharmaceutical Recent Developments
Table 150. Cheng Du Sheng Nuo Biotec Corporation Information
Table 151. Cheng Du Sheng Nuo Biotec Description and Major Businesses
Table 152. Cheng Du Sheng Nuo Biotec Product Models, Descriptions and Specifications
Table 153. Cheng Du Sheng Nuo Biotec Sales (Tons), Revenue (US$ Million), Price (US$/kg) and Gross Margin (2020-2025)
Table 154. Cheng Du Sheng Nuo Biotec Recent Developments
Table 155. Hybio Pharmaceutical Corporation Information
Table 156. Hybio Pharmaceutical Description and Major Businesses
Table 157. Hybio Pharmaceutical Product Models, Descriptions and Specifications
Table 158. Hybio Pharmaceutical Sales (Tons), Revenue (US$ Million), Price (US$/kg) and Gross Margin (2020-2025)
Table 159. Hybio Pharmaceutical Recent Developments
Table 160. Hainan Shuangcheng Pharmaceuticals Corporation Information
Table 161. Hainan Shuangcheng Pharmaceuticals Description and Major Businesses
Table 162. Hainan Shuangcheng Pharmaceuticals Product Models, Descriptions and Specifications
Table 163. Hainan Shuangcheng Pharmaceuticals Sales (Tons), Revenue (US$ Million), Price (US$/kg) and Gross Margin (2020-2025)
Table 164. Hainan Shuangcheng Pharmaceuticals Recent Developments
Table 165. Guangdong Jianyuan Pharmaceutical Corporation Information
Table 166. Guangdong Jianyuan Pharmaceutical Description and Major Businesses
Table 167. Guangdong Jianyuan Pharmaceutical Product Models, Descriptions and Specifications
Table 168. Guangdong Jianyuan Pharmaceutical Sales (Tons), Revenue (US$ Million), Price (US$/kg) and Gross Margin (2020-2025)
Table 169. Guangdong Jianyuan Pharmaceutical Recent Developments
Table 170. Zhejiang Peptites Biotech Corporation Information
Table 171. Zhejiang Peptites Biotech Description and Major Businesses
Table 172. Zhejiang Peptites Biotech Product Models, Descriptions and Specifications
Table 173. Zhejiang Peptites Biotech Sales (Tons), Revenue (US$ Million), Price (US$/kg) and Gross Margin (2020-2025)
Table 174. Zhejiang Peptites Biotech Recent Developments
Table 175. Key Raw Materials Distribution
Table 176. Raw Materials Key Suppliers
Table 177. Critical Raw Material Supplier Concentration (2024) & Risk Index
Table 178. Milestones in Production Technology Evolution
Table 179. Distributors List
Table 180. Market Trends and Market Evolution
Table 181. Market Drivers and Opportunities
Table 182. Market Challenges, Risks, and Restraints
Table 183. Research Programs/Design for This Report
Table 184. Key Data Information from Secondary Sources
Table 185. Key Data Information from Primary Sources


List of Figures
Figure 1. Therapeutic Peptide APIs Product Picture
Figure 2. Global Therapeutic Peptide APIs Market Size Growth Rate by Type, 2020 VS 2024 VS 2031 (US$ Million)
Figure 3. Bioactive Peptides Product Picture
Figure 4. Synthetic Peptides Product Picture
Figure 5. Global Therapeutic Peptide APIs Market Size Growth Rate by Application, 2020 VS 2024 VS 2031 (US$ Million)
Figure 6. Pharmaceuticals
Figure 7. Scientific Research
Figure 8. Other
Figure 9. Therapeutic Peptide APIs Report Years Considered
Figure 10. Global Therapeutic Peptide APIs Revenue, (US$ Million), 2020 VS 2024 VS 2031
Figure 11. Global Therapeutic Peptide APIs Revenue (2020-2031) & (US$ Million)
Figure 12. Global Therapeutic Peptide APIs Revenue (CAGR) by Region: 2020 VS 2024 VS 2031 (US$ Million)
Figure 13. Global Therapeutic Peptide APIs Revenue Market Share by Region (2020-2031)
Figure 14. Global Therapeutic Peptide APIs Sales (2020-2031) & (Tons)
Figure 15. Global Therapeutic Peptide APIs Sales (CAGR) by Region (2020-2031) (Tons)
Figure 16. Global Therapeutic Peptide APIs Sales Market Share by Region (2020-2031)
Figure 17. Top 5 and Top 10 Manufacturers Therapeutic Peptide APIs Sales Volume Market Share in 2024
Figure 18. Global Therapeutic Peptide APIs Revenue Market Share Ranking (2024)
Figure 19. Tier Distribution by Revenue Contribution (2020 VS 2024)
Figure 20. Bioactive Peptides Revenue Market Share by Manufacturer in 2024
Figure 21. Synthetic Peptides Revenue Market Share by Manufacturer in 2024
Figure 22. Global Therapeutic Peptide APIs Sales Market Share by Type (2020-2031)
Figure 23. Global Therapeutic Peptide APIs Revenue Market Share by Type (2020-2031)
Figure 24. Global Therapeutic Peptide APIs Sales Market Share by Application (2020-2031)
Figure 25. Global Therapeutic Peptide APIs Revenue Market Share by Application (2020-2031)
Figure 26. North America Therapeutic Peptide APIs Sales YoY (2020-2031) & (Tons)
Figure 27. North America Therapeutic Peptide APIs Revenue YoY (2020-2031) & (US$ Million)
Figure 28. North America Top 5 Manufacturers Therapeutic Peptide APIs Sales Revenue (US$ Million) in 2024
Figure 29. North America Therapeutic Peptide APIs Sales Volume (Tons) by Type (2020- 2031)
Figure 30. North America Therapeutic Peptide APIs Sales Revenue (US$ Million) by Type (2020 - 2031)
Figure 31. North America Therapeutic Peptide APIs Sales Volume (Tons) by Application (2020-2031)
Figure 32. North America Therapeutic Peptide APIs Sales Revenue (US$ Million) by Application (2020-2031)
Figure 33. US Therapeutic Peptide APIs Revenue (2020-2031) & (US$ Million)
Figure 34. Canada Therapeutic Peptide APIs Revenue (2020-2031) & (US$ Million)
Figure 35. Mexico Therapeutic Peptide APIs Revenue (2020-2031) & (US$ Million)
Figure 36. Europe Therapeutic Peptide APIs Sales YoY (2020-2031) & (Tons)
Figure 37. Europe Therapeutic Peptide APIs Revenue YoY (2020-2031) & (US$ Million)
Figure 38. Europe Top 5 Manufacturers Therapeutic Peptide APIs Sales Revenue (US$ Million) in 2024
Figure 39. Europe Therapeutic Peptide APIs Sales Volume (Tons) by Type (2020-2031)
Figure 40. Europe Therapeutic Peptide APIs Sales Revenue (US$ Million) by Type (2020-2031)
Figure 41. Europe Therapeutic Peptide APIs Sales Volume (Tons) by Application (2020-2031)
Figure 42. Europe Therapeutic Peptide APIs Sales Revenue (US$ Million) by Application (2020-2031)
Figure 43. Germany Therapeutic Peptide APIs Revenue (2020-2031) & (US$ Million)
Figure 44. France Therapeutic Peptide APIs Revenue (2020-2031) & (US$ Million)
Figure 45. U.K. Therapeutic Peptide APIs Revenue (2020-2031) & (US$ Million)
Figure 46. Italy Therapeutic Peptide APIs Revenue (2020-2031) & (US$ Million)
Figure 47. Russia Therapeutic Peptide APIs Revenue (2020-2031) & (US$ Million)
Figure 48. Asia-Pacific Therapeutic Peptide APIs Sales YoY (2020-2031) & (Tons)
Figure 49. Asia-Pacific Therapeutic Peptide APIs Revenue YoY (2020-2031) & (US$ Million)
Figure 50. Asia-Pacific Top 8 Manufacturers Therapeutic Peptide APIs Sales Revenue (US$ Million) in 2024
Figure 51. Asia-Pacific Therapeutic Peptide APIs Sales Volume (Tons) by Type (2020- 2031)
Figure 52. Asia-Pacific Therapeutic Peptide APIs Sales Revenue (US$ Million) by Type (2020- 2031)
Figure 53. Asia-Pacific Therapeutic Peptide APIs Sales Volume (Tons) by Application (2020-2031)
Figure 54. Asia-Pacific Therapeutic Peptide APIs Sales Revenue (US$ Million) by Application (2020-2031)
Figure 55. Indonesia Therapeutic Peptide APIs Revenue (2020-2031) & (US$ Million)
Figure 56. Japan Therapeutic Peptide APIs Revenue (2020-2031) & (US$ Million)
Figure 57. South Korea Therapeutic Peptide APIs Revenue (2020-2031) & (US$ Million)
Figure 58. China Taiwan Therapeutic Peptide APIs Revenue (2020-2031) & (US$ Million)
Figure 59. India Therapeutic Peptide APIs Revenue (2020-2031) & (US$ Million)
Figure 60. Central and South America Therapeutic Peptide APIs Sales YoY (2020-2031) & (Tons)
Figure 61. Central and South America Therapeutic Peptide APIs Revenue YoY (2020-2031) & (US$ Million)
Figure 62. Central and South America Top 5 Manufacturers Therapeutic Peptide APIs Sales Revenue (US$ Million) in 2024
Figure 63. Central and South America Therapeutic Peptide APIs Sales Volume (Tons) by Type (2021-2031)
Figure 64. Central and South America Therapeutic Peptide APIs Sales Revenue (US$ Million) by Type (2020-2031)
Figure 65. Central and South America Therapeutic Peptide APIs Sales Volume (Tons) by Application (2020-2031)
Figure 66. Central and South America Therapeutic Peptide APIs Sales Revenue (US$ Million) by Application (2020-2031)
Figure 67. Brazil Therapeutic Peptide APIs Revenue (2020-2025) & (US$ Million)
Figure 68. Argentina Therapeutic Peptide APIs Revenue (2020-2025) & (US$ Million)
Figure 69. Middle East, and Africa Therapeutic Peptide APIs Sales YoY (2020-2031) & (Tons)
Figure 70. Middle East and Africa Therapeutic Peptide APIs Revenue YoY (2020-2031) & (US$ Million)
Figure 71. Middle East and Africa Top 5 Manufacturers Therapeutic Peptide APIs Sales Revenue (US$ Million) in 2024
Figure 72. Middle East and Africa Therapeutic Peptide APIs Sales Volume (Tons) by Type (2021-2031)
Figure 73. South America Therapeutic Peptide APIs Sales Revenue (US$ Million) by Type (2020-2031)
Figure 74. Middle East and Africa Therapeutic Peptide APIs Sales Volume (Tons) by Application (2020-2031)
Figure 75. Middle East and Africa Therapeutic Peptide APIs Sales Revenue (US$ Million) by Application (2020-2031)
Figure 76. GCC Countries Therapeutic Peptide APIs Revenue (2020-2025) & (US$ Million)
Figure 77. Turkey Therapeutic Peptide APIs Revenue (2020-2025) & (US$ Million)
Figure 78. Egypt Therapeutic Peptide APIs Revenue (2020-2025) & (US$ Million)
Figure 79. South Africa Therapeutic Peptide APIs Revenue (2020-2025) & (US$ Million)
Figure 80. Therapeutic Peptide APIs Industry Chain Mapping
Figure 81. Regional Therapeutic Peptide APIs Manufacturing Base Distribution (%)
Figure 82. Global Therapeutic Peptide APIs Production Market Share by Region (2020-2031)
Figure 83. Therapeutic Peptide APIs Production Process
Figure 84. Regional Therapeutic Peptide APIs Production Cost Structure
Figure 85. Channels of Distribution (Direct Vs Distribution)
Figure 86. Bottom-up and Top-down Approaches for This Report
Figure 87. Data Triangulation
Figure 88. Key Executives Interviewed

Your Name

Your E-mail

Your message

Submit